(Q42543595)

2 November 2017

Aminorex, dexfenfluramine, and primary pulmonary hypertension (English)

1 reference

2 November 2017

Kramer MS

1

1 reference

PubMed ID

9539893

2 November 2017

Lane DA

series ordinal

2

1 reference

2 November 2017

1 April 1998

1 reference

Journal of Clinical Epidemiology

2 November 2017

1 reference

2 November 2017

51

1 reference

2 November 2017

4

1 reference

2 November 2017

361-364

1 reference

Primary pulmonary hypertension and cirrhosis: are they related?

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Primary pulmonary hypertension and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Pulmonary hypertension and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Aminorex and the pulmonary circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Drug-induced Pulmonary Hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Primary pulmonary hypertension and fenfluramine use

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Drug-induced pulmonary hypertension: must history repeat itself?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Estimability and estimation in case-referent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Neurobiology of an anorectic drug: fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

MAO-inhibitory properties of anorectic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900289-8

7 January 2021

10.1016/S0895-4356(97)00289-8

Identifiers

DOI

1 reference

2 November 2017

1 reference

PubMed ID

9539893